HighTower Advisors LLC Lowers Stake in Hologic, Inc. (NASDAQ:HOLX)

HighTower Advisors LLC lowered its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 26.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 16,568 shares of the medical equipment provider's stock after selling 6,035 shares during the quarter. HighTower Advisors LLC's holdings in Hologic were worth $1,194,000 as of its most recent filing with the SEC.

Several other hedge funds also recently made changes to their positions in HOLX. General Partner Inc. purchased a new position in Hologic during the fourth quarter worth about $26,000. Groupama Asset Managment raised its stake in shares of Hologic by 9.9% during the 3rd quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider's stock worth $27,000 after buying an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC raised its stake in shares of Hologic by 156.3% during the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock worth $31,000 after buying an additional 261 shares in the last quarter. First Horizon Advisors Inc. lifted its holdings in shares of Hologic by 38.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider's stock valued at $39,000 after buying an additional 134 shares during the period. Finally, Smartleaf Asset Management LLC boosted its position in shares of Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the stock. Morgan Stanley dropped their target price on shares of Hologic from $84.00 to $82.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Royal Bank of Canada reduced their price objective on Hologic from $88.00 to $85.00 and set a "sector perform" rating for the company in a report on Thursday, February 6th. Evercore ISI decreased their target price on Hologic from $76.00 to $73.00 and set an "in-line" rating on the stock in a research report on Thursday, February 6th. Needham & Company LLC cut Hologic from a "buy" rating to a "hold" rating and set a $90.00 price target for the company. in a research report on Monday, February 3rd. Finally, Citigroup decreased their price objective on shares of Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a research report on Tuesday, March 4th. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Hologic presently has a consensus rating of "Hold" and a consensus target price of $84.62.

Hologic Trading Down 1.6 %

HOLX stock traded down $1.00 during midday trading on Friday, hitting $61.32. The stock had a trading volume of 1,110,999 shares, compared to its average volume of 1,809,690. The company's 50-day moving average price is $65.24 and its 200 day moving average price is $73.29. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a market cap of $13.76 billion, a PE ratio of 19.34, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. Hologic, Inc. has a 12-month low of $60.34 and a 12-month high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities research analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.